Abstract:Importance: Patients with breast cancer and comorbid HIV experience higher mortality than other patients with breast cancer. Objective: To compare time to cancer treatment initiation and relative dose intensity (RDI) of neoadjuvant and adjuvant chemotherapy among patients with breast cancer with vs without HIV. Design, setting, and participants: A retrospective, matched cohort study enrolled women who received a diagnosis of breast cancer from January 1, 2000, through December 31, 2018. The electronic medical records of 3 urban, academic cancer centers were searched for women with confirmed HIV infection prior to or simultaneous with diagnosis of stage I to III breast cancer. Tumor registry data were used to identify 2 control patients with breast cancer without HIV for each participant with HIV, matching for study site, stage, and year of cancer diagnosis. Statistical analysis was performed from December 2022 to October 2023. Exposure: HIV infection detected before or within 90 days of participants' breast cancer diagnosis. Main outcomes and measures: The primary outcome was time to breast cancer treatment initiation, defined as the number of days between cancer diagnosis and first treatment. The secondary outcome was overall RDI for patients who received chemotherapy. These outcomes were compared by HIV status using Cox proportional hazards regression and linear regression modeling, respectively, adjusting for confounding demographic and clinical factors. Exploratory outcomes included instances of anemia, neutropenia, thrombocytopenia, and liver function test result abnormalities during chemotherapy, which were compared using Fisher exact tests. Results: The study enrolled 66 women with comorbid breast cancer and HIV (median age, 51.1 years [IQR, 45.7-58.2 years]) and 132 with breast cancer alone (median age, 53.9 years [IQR, 47.0-62.5 years]). The median time to first cancer treatment was not significantly higher among patients with HIV than those without (48.5 days [IQR, 32.0-67.0 days] vs 42.5 days [IQR, 25.0-59.0 days]; adjusted hazard ratio, 0.78, 95% CI, 0.55-1.12). Among the 36 women with HIV and 62 women without HIV who received chemotherapy, the median overall RDI was lower for those with HIV vs without HIV (0.87 [IQR, 0.74-0.97] vs 0.96 [IQR, 0.88-1.00]; adjusted P = .01). Grade 3 or higher neutropenia during chemotherapy occurred among more women with HIV than those without HIV (13 of 36 [36.1%] vs 5 of 58 [8.6%]). Conclusions and relevance: This matched cohort study suggests that patients with breast cancer and HIV may have experienced reduced adjuvant chemotherapy RDI, reflecting greater dose reductions, delays, or discontinuation. Strategies for supporting this vulnerable population during chemotherapy treatment are necessary.

HIV and Breast Cancer—A Critical Review

HIV and HPV Interplay in Cervical Cancer—A Comprehensive Review

Atherosclerosis and Cardiovascular Complications in People Living with HIV: A Focused Review

Exploring the application of immunotherapy against HIV infection in the setting of malignancy: A detailed review article

A clinical overview of people living with HIV and genitourinary cancer care

Cancer and HIV: The Molecular Mechanisms of the Deadly Duo

Are Non-HIV Malignancies Increased in the HIV-Infected Population?

Cancer immunotherapy in adult patients with HIV

Time to Cancer Treatment and Chemotherapy Relative Dose Intensity for Patients With Breast Cancer Living With HIV

Cervical cancer prevention and control in women living with human immunodeficiency virus

A Comprehensive Review of HIV-Associated Tuberculosis: Clinical Challenges and Advances in Management

Cervical precancer and invasive cancer among women living with HIV in Latin America: A systematic review and meta-analysis

The impact of concurrent HIV-infection on women with vulvar cancer: Comparison of clinical characteristics and outcome

Current management of cervical cancer in women living with HIV

Non-Melanoma Skin Cancer in People Living With HIV: From Epidemiology to Clinical Management

State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI

Enhanced cervical cancer and HIV interventions reduce the disproportionate burden of cervical cancer cases among women living with HIV: A modeling analysis

Atherosclerosis and HIV: Exploring Cardiovascular Risks and Management

Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus

Malignancies in HIV-Infected and AIDS Patients.

Cancer Treatment Disparities in People With HIV in the United States, 2001-2019